ABVC BioPharma ABVC Stock
ABVC BioPharma Price Chart
ABVC BioPharma ABVC Financial and Trading Overview
| ABVC BioPharma stock price | 1.09 USD |
| Previous Close | 0.94 USD |
| Open | 0.89 USD |
| Bid | 0 USD x 800 |
| Ask | 0 USD x 1400 |
| Day's Range | 0.86 - 0.91 USD |
| 52 Week Range | 0.82 - 18.7 USD |
| Volume | 38.01K USD |
| Avg. Volume | 821.42K USD |
| Market Cap | 3.69M USD |
| Beta (5Y Monthly) | 0.314315 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.43 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
ABVC Valuation Measures
| Enterprise Value | 9.09M USD |
| Trailing P/E | N/A |
| Forward P/E | -1.9736363 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 4.825411 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 11.874 |
| Enterprise Value/EBITDA | -0.832 |
Trading Information
ABVC BioPharma Stock Price History
| Beta (5Y Monthly) | 0.314315 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 18.7 USD |
| 52 Week Low | 0.82 USD |
| 50-Day Moving Average | 1.71 USD |
| 200-Day Moving Average | 5.38 USD |
ABVC Share Statistics
| Avg. Volume (3 month) | 821.42K USD |
| Avg. Daily Volume (10-Days) | 64.08K USD |
| Shares Outstanding | 3.95M |
| Float | 2.68M |
| Short Ratio | 0.13 |
| % Held by Insiders | 38.99% |
| % Held by Institutions | 2.00% |
| Shares Short | 19.31K |
| Short % of Float | 1.05% |
| Short % of Shares Outstanding | 0.48% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:18 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | June 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -1430.019% |
| Gross Margin | 46.53% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -59.23% |
| Return on Equity (ttm) | -283.42% |
Income Statement
| Revenue (ttm) | 765.64K USD |
| Revenue Per Share (ttm) | 0.23 USD |
| Quarterly Revenue Growth (yoy) | -98.00000000000000000000000000000000% |
| Gross Profit (ttm) | N/A |
| EBITDA | -10922470 USD |
| Net Income Avi to Common (ttm) | -12656008 USD |
| Diluted EPS (ttm) | -3.58 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 176.08K USD |
| Total Cash Per Share (mrq) | 0.05 USD |
| Total Debt (mrq) | 5.85M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.369 |
| Book Value Per Share (mrq) | -0.116 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -3372233 USD |
| Levered Free Cash Flow (ttm) | 2.9M USD |
Profile of ABVC BioPharma
| Country | United States |
| State | CA |
| City | Fremont |
| Address | 44370 Old Warm Springs Boulevard |
| ZIP | 94538 |
| Phone | (510)-668-0881 |
| Website | https://www.abvcpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 19 |
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.
Q&A For ABVC BioPharma Stock
What is a current ABVC stock price?
ABVC BioPharma ABVC stock price today per share is 1.09 USD.
How to purchase ABVC BioPharma stock?
You can buy ABVC shares on the NasdaqCM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for ABVC BioPharma?
The stock symbol or ticker of ABVC BioPharma is ABVC.
Which industry does the ABVC BioPharma company belong to?
The ABVC BioPharma industry is Biotechnology.
How many shares does ABVC BioPharma have in circulation?
The max supply of ABVC BioPharma shares is 10.56M.
What is ABVC BioPharma Price to Earnings Ratio (PE Ratio)?
ABVC BioPharma PE Ratio is now.
What was ABVC BioPharma earnings per share over the trailing 12 months (TTM)?
ABVC BioPharma EPS is -2.43 USD over the trailing 12 months.
Which sector does the ABVC BioPharma company belong to?
The ABVC BioPharma sector is Healthcare.
ABVC BioPharma ABVC included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16175.09 USD — |
-1.62
|
3.94B USD — | 16125.33 USD — | 16341.46 USD — | — - | 3.94B USD — |
| NASDAQ HealthCare IXHC | 958.68 USD — |
-2.07
|
— — | 954.08 USD — | 972.42 USD — | — - | — — |
- {{ link.label }} {{link}}